We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Horizon Discovery and AstraZeneca win “Licensing Deal of the Year” at Scrip Awards 2013
News

Horizon Discovery and AstraZeneca win “Licensing Deal of the Year” at Scrip Awards 2013

Horizon Discovery and AstraZeneca win “Licensing Deal of the Year” at Scrip Awards 2013
News

Horizon Discovery and AstraZeneca win “Licensing Deal of the Year” at Scrip Awards 2013

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Horizon Discovery and AstraZeneca win “Licensing Deal of the Year” at Scrip Awards 2013"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Horizon Discovery has won “Licensing Deal of the Year” at the Scrip Awards 2013, for their agreement with AstraZeneca. The Scrip Awards are highly prestigious, recognizing excellence in both pharma and biotech companies and those firms that support them.

The HD-001 program has the potential to be developed into a treatment based on modulation of a novel kinase. This target has been shown to be mutated in a range of cancer types including colon and lung. Importantly, the target has also been shown to play a key role in K-Ras mutant tumours. K-Ras is mutated in up to 40% of all cancer types causing resistance to many of the available targeted therapeutics and as a result is associated with poor patient outcomes, which makes the development of molecular targeted therapies against the gene a significant unmet need. A case study on the development of the HD-001 program can be found here: www.horizondiscovery.com/media/item/67

Dr Chris Torrance, CSO and leader of the HD-001 program at Horizon, commented: “We were excited to partner this program with AstraZeneca, and we have made good progress since the start of the collaboration. We are delighted that the quality of the program has now also been recognised by Scrip, and are honored to accept the award.”

Advertisement